Alaunos Therapeutics
TCRT
108 hedge funds and large institutions have $44.7M invested in Alaunos Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 17 closing their positions.
3,109% more call options, than puts
Call options by funds: $5.23M | Put options by funds: $163K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.22% → 0.2% (-0.02%)
11% less funds holding
Funds holding: 121 → 108 (-13)
15% less capital invested
Capital invested by funds: $52.9M → $44.7M (-$8.17M)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$684K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$92.5K |
| 3 |
Millennium Management
New York
|
+$91.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.5K |
| 5 |
Squarepoint
New York
|
+$60.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Addison Capital
Conshohocken,
Pennsylvania
|
-$2.32M |
| 2 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
-$1.73M |
| 3 |
Morgan Stanley
New York
|
-$480K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$456K |
| 5 |
Two Sigma Investments
New York
|
-$416K |
TCRT Hedge Fund Activity: Q1 2023 in Review
108 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2023, worth a combined $44.7M — down 15% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TCRT and 8 opened new positions — a net loss of 9 holders — while 29 trimmed existing stakes and 24 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $684K. The largest seller was Addison Capital, exiting entirely with an estimated $2.32M sold.
- 108 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2023, down from 121 in Q4 2022.
- Funds reported $44.7M of Alaunos Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 8 funds opened new Alaunos Therapeutics positions in Q1 2023 and 17 closed out, a net change of -9 holders.
- The largest Alaunos Therapeutics buyer in Q1 2023 was Jacobs Levy Equity Management, an estimated $684K added.
- The largest Alaunos Therapeutics seller in Q1 2023 was Addison Capital, an estimated $2.32M sold.
Based on aggregated 13F filings for Q1 2023.